Parkinson’s UK Continues to Support Keapstone’s Quest to Develop Treatments for MND and Parkinson’s
With its recent award of £1 million (about $1.3 million USD), Parkinson’s UK continues to invest in Keapstone Therapeutics, bringing the biotechnology company closer to developing treatments for Parkinson’s and motor neuron disease (MND), it was announced. Keapstone officials also hope the funding, which will go toward…